New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 28, 2014
06:22 EDTHZNP, ESRX, CVSHorizon Pharma said Duexis, Vimovo to be placed on CVS, Express exlclusion lists
Horizon Pharma (HZNP) said it has been verbally notified that in August, two pharmacy benefit managers, CVS Caremark (CVS) and Express Scripts (ESRX), expect to announce DUEXIS and VIMOVO will no longer be on their formularies and will be placed on their exclusion lists effective January 1, 2015. As a change in Caremark and ESI formulary status would not take effect until 2015, Horizon Pharma does not expect this potential action to impact the financial guidance of $270M-280M for net revenues and $80M-90M for adjusted EBITDA for fiscal 2014 as provided in first quarter earnings press release dated May 9. In response to potentially being placed on Caremarkís and ESIís exclusion lists, the company said it will immediately accelerate patient and physician focused commercial model to focus prescriptions through other channels such as our Prescriptions Made Easy program, continue working with many of the other PBMs and evaluate price increases. We estimate approximately 20%-30% of DUEXIS and VIMOVO prescriptions could be impacted by the potential actions by Caremark and ESI. In the future, if additional healthcare plans adopt the Caremark or ESI exclusion lists or otherwise exclude DUEXIS or VIMOVO from the formularies they use, which they are not required to do, there could possibly be additional DUEXIS and VIMOVO prescriptions affected.
News For HZNP;CVS;ESRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 7, 2015
08:45 EDTHZNPDepomed volatility low into Horizon Pharma proposal to acquire
Subscribe for More Information
08:32 EDTHZNPHorizon Pharma to hold a conference call
Subscribe for More Information
08:17 EDTHZNPHorizon Pharma volatility low into proposal to acquire Depomed
Horizon Pharma (HZNP) July call option implied volatility is at 47, August is at 56; compared to its 52-week range of 40 to 100, suggesting low price movement into announcing a proposal to acquire all outstanding shares of Depomed (DEPO) for a per share consideration of $29.25 in an all-stock, tax-free exchange valued at approximately $3B.
07:06 EDTHZNPHorizon Pharma proposes to acquire Depomed for $29.25/share in all-stock deal
Subscribe for More Information
07:04 EDTHZNPHorizon Pharma proposes to acquire Depomed for $29.25/share in all-stock deal
Subscribe for More Information
July 6, 2015
11:16 EDTCVS, ESRXAetna-Humana tie-up may present longer term opportunity for CVS, says JPMorgan
Subscribe for More Information
07:10 EDTHZNPHorizon Pharma files patent infringement lawsuits against five companies
Subscribe for More Information
July 2, 2015
07:03 EDTHZNPHorizon Pharma announces USPTO issuance of Notice of Allowance
Subscribe for More Information
June 29, 2015
11:21 EDTESRXMorgan Stanley reports 5% passive stake in Express Scripts
Subscribe for More Information
June 26, 2015
07:28 EDTHZNPHorizon Pharma price target raised to $40 from $32 at UBS
Subscribe for More Information
June 25, 2015
05:48 EDTESRXStocks with implied volatility movement; SDS ESRX
Stocks with implied volatility movement; UltraShort S&P500 ProShares (SDS) 28, Express Scripts (ESRX) 27 according to iVolatility.
June 24, 2015
14:13 EDTESRXExpress Scripts July weekly volatility elevated as shares near record high
Subscribe for More Information
08:33 EDTCVSCVS Health enters into four new clinical affiliations
CVS Health has entered into new clinical affiliations with Sutter Health in California, Millennium Physician Group in Florida, Bryan Health Connect in Nebraska and Mount Kisco Medical Group, PC in New York. Through these clinical affiliations, CVS Health will provide prescription and visit information to the participating health care organizations.
June 23, 2015
10:54 EDTCVSCVS Health expects to complete $5B in share repurchases in 2015
10:40 EDTCVSCVS Health sees Omnicare transaction closing by end of year
Subscribe for More Information
10:31 EDTCVSCVS Health names Norman de Greve as Chief Marketing Officer, effective July 15
CVS Health announced that Norman de Greve will join CVS Health as Chief Marketing Officer, effective July 15. In this role, de Greve will be accountable for marketing strategy across the enterprise. He is currently the President of the Boston and Detroit offices of DigitasLBi.
07:36 EDTHZNPJMP Securities to hold a conference
Subscribe for More Information
07:12 EDTHZNPHorizon Pharma announces notice of allowance with claims covering Ravicti
Horizon Pharma announced that it has received from the United States Patent and Trademark Office a Notice of Allowance for U.S. patent application number 13/775,000, entitled "Methods of Therapeutic Monitoring of Nitrogen Scavenging Drugs" that covers Horizon's U.S. approved product Ravicti Oral Liquid.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use